The Effect of Dexmedetomidine During Opioid Free Anesthesia on Postoperative Recovery After Gastrectomy
Condition: Gastric Cancer
MeSH terms: Stomach Neoplasms
Study type: Interventional

Summary: 
      "Want to know the effect of dexmedetomidine during opioid free anesthesia on postoperative
      recovery after gastrectomy. Patients undergoing open gastrectomy are divided into
      dexmedetomidine group and control(remifentanil) group, administered during surgery, and
      compared with the speed of postoperative intestinal function recovery. Based on our
      institution's previous record, the average recovery time was 6 ± 1.4 days. Given that it is
      clinically significant to reduce recovery time by 20%, Alpha 0.05 and Power 80% require 31
      samples per group, and assuming a 10% dropout rate, the total number of samples needed is
      68.Subjects are patients aged 19 to 75 who are subject to open gastretomy planned by a
      gastric cancer. The exclusion criteria include American Society of Anesthesiology grade 3 or
      higher, patients who have previously been treated for cancer, patients with cancer other than
      the stomach, patients with drug allergies, weight less than 60kg, BMI > 30 kg/m2, patients
      who are unable to communicate and are unable to read consent (e.g., illiteracy, foreigners,
      etc.). The research method is a Randomized double-blind controlled study, and the assignment
      of both drugs is unknown and is used to maintain anesthesia in the form of continuous
      injection during surgery. Primary outcome is the recovery period satisfying the following.
      1)intestinal gas passage 2) tolerance of soft bland diet (SBD) for 24 hr. 3) safe ambulation
      without assistance 4) no requirement iv analgesics after discontinuation of PCA (VAS <4). 5)
      no abnormal physical signs or laboratory test. The secondary outcomes are maximum VAS,
      post-operative hospital stay, complications and readmission rate at 3 months F/U time,
      post-operative period analgesic requirement, incidence of opioid related side effect.
    


Intervention name(s): Dexmedetomidine; Remifentanil
Intervention type(s): Drug; Drug
Intervention description(s): The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.; The prepared drug marks the assigned group as unknown. In both groups, the test drug marked as unknown begins to be administered in an anesthetic induction. When the patient arrives in the operating room, electrocardiogram, noninvasive blood pressure, and bispectral index (BIS) monitoring is performed. In both groups, 2 mg/kg of propofol induces general anesthesia, intubates after administration of rocuronium 0.6 mg/kg, and maintains anesthesia with sevoflurane 1.5-2.5 vol%. Use 0.075 mg of palonosetrone as an antiemetics after inducing anesthesia. Adjust the inhalation anesthetic to maintain BIS 40-60 , mechanical ventilation to maintain the Tidal volume of 8 ml/kg, PEEP 5 mmHg and end-tidal carbon dioxide (EtCO2) of 35-40 mmHg. Push 1mcg of fentanyl and 1g of acetaminophen per kg for pain control 20 minutes before the end of surgery.
Intervention MeSH terms: Dexmedetomidine; Remifentanil
Allocation: Randomized
Intervention model: Parallel Assignment
Intervention model description: Randomized Double-blind Controlled Study
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment